Literature DB >> 16246623

DNA microarray genotyping of N-acetyltransferase 2 polymorphism using carbodiimide as the linker for assessment of isoniazid hepatotoxicity.

Yasuo Shimizu1, Kunio Dobashi, Yoshihiro Mita, Katsuaki Endou, Shogo Moriya, Kaoru Osano, Yoko Koike, Seiichi Higuchi, Shigeki Yabe, Mitsuyoshi Utsugi, Tamotsu Ishizuka, Takeshi Hisada, Tsugio Nakazawa, Masatomo Mori.   

Abstract

The antituberculous drug isoniazid (INH) is acetylated by N-acetyltransferase 2 (NAT2), and the frequency of INH-induced hepatotoxicity is determined by the NAT2 genotype. NAT2 genotyping is not done routinely in hospital laboratories because of its difficulty. Use of microarrays for research is becoming common and its expectations of clinical application are increasing. In this study, we attempted to develop an easier method of NAT2 genotyping for clinical use. We devised a novel oligonucleotide-based DNA microarray for NAT2 genotyping using a recently developed technique for attaching oligonucleotide probes to poly carbodiimide-coated glass slides, which achieves a stronger hybridization signal and better specificity than the more widely used aminosilane-coated slides. To assess the validity of this microarray, four clones with NAT2 mutations and DNA from 42 tuberculosis patients were investigated by the microarray method and by restriction fragment length polymorphism analysis. The results of genotyping by these two methods were in agreement. Analysis of the relationship between the NAT2 phenotype determined by the DNA microarray and the risk of INH-induced hepatotoxicity revealed that slow acetylators had a significantly higher risk. These findings suggest that our microarray may be clinically useful for predicting drug reactions to INH.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16246623     DOI: 10.1016/j.tube.2005.09.002

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  14 in total

Review 1.  Risk factors for idiosyncratic drug-induced liver injury.

Authors:  Naga Chalasani; Einar Björnsson
Journal:  Gastroenterology       Date:  2010-04-12       Impact factor: 22.682

2.  Slow N-acetyltransferase 2 genotype contributes to anti-tuberculosis drug-induced hepatotoxicity: a meta-analysis.

Authors:  Haijian Du; Xiaorong Chen; Yi Fang; Ouyang Yan; Hong Xu; Li Li; Weifeng Li; Wenjie Huang
Journal:  Mol Biol Rep       Date:  2013-01-01       Impact factor: 2.316

3.  PharmGKB summary: isoniazid pathway, pharmacokinetics.

Authors:  Daniel J Klein; Sotiria Boukouvala; Ellen M McDonagh; Scott R Shuldiner; Nicola Laurieri; Caroline F Thorn; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2016-09       Impact factor: 2.089

4.  NAT2 variants and toxicity related to anti-tuberculosis agents: a systematic review and meta-analysis.

Authors:  M Richardson; J Kirkham; K Dwan; D J Sloan; G Davies; A L Jorgensen
Journal:  Int J Tuberc Lung Dis       Date:  2019-03-01       Impact factor: 2.373

5.  NAT2 6A, a haplotype of the N-acetyltransferase 2 gene, is an important biomarker for risk of anti-tuberculosis drug-induced hepatotoxicity in Japanese patients with tuberculosis.

Authors:  Norihide Higuchi; Naoko Tahara; Katsunori Yanagihara; Kiyoyasu Fukushima; Naofumi Suyama; Yuichi Inoue; Yoshitsugu Miyazaki; Tsutomu Kobayashi; Kohichiro Yoshiura; Norio Niikawa; Chun-Yang Wen; Hajime Isomoto; Saburou Shikuwa; Katsuhisa Omagari; Yohei Mizuta; Shigeru Kohno; Kazuhiro Tsukamoto
Journal:  World J Gastroenterol       Date:  2007-12-07       Impact factor: 5.742

6.  Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.

Authors:  Ryuji Kubota; Masako Ohno; Tomoko Hasunuma; Hajime Iijima; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2007-07-31       Impact factor: 2.953

Review 7.  PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2.

Authors:  Ellen M McDonagh; Sotiria Boukouvala; Eleni Aklillu; David W Hein; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2014-08       Impact factor: 2.089

8.  Distribution of allelic and genotypic frequencies of NAT2 and CYP2E1 variants in Moroccan population.

Authors:  Soukaina Guaoua; Ilham Ratbi; Fatima Zahra Laarabi; Siham Chafai Elalaoui; Imane Cherkaoui Jaouad; Amina Barkat; Abdelaziz Sefiani
Journal:  BMC Genet       Date:  2014-12-29       Impact factor: 2.797

9.  Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis.

Authors:  Yu Cai; JiaYong Yi; ChaoHui Zhou; XiZhong Shen
Journal:  PLoS One       Date:  2012-10-17       Impact factor: 3.240

10.  Five-antituberculosis Drug-resistance Genes Detection Using Array System.

Authors:  Yasuo Shimizu; Kunio Dobashi; Yoko Yoshikawa; Shigeki Yabe; Seiichi Higuchi; Yoko Koike; Yoshihiro Mita; Mitsuyoshi Utsugi; Katsuaki Endou; Kouichi Takahashi; Satoru Watanabe; Ryusei Saito; Masatomo Mori
Journal:  J Clin Biochem Nutr       Date:  2008-05       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.